TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01922362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure drainage system
Description: a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect wet dressing
Description: The recipient site wound is covered with sulfa-tula first and then wet gauze.
Study: NCT04517344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Flow Rate
Description: Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Flow Rate
Description: Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Flow Rate
Description: Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
Study: NCT03116906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: to be given for a total of up to 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to be given for a total of up to 15 days
Study: NCT04675736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: brushing force
Description: Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
Study: NCT01823536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Description: Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Study: NCT00233090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: single dose of 200 mg. a day of modafinil for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily dose of placebo for four weeks.
Study: NCT03601975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine/Cisplatin
Description: gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
Study: NCT03758209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prehabilitation + ERAS
Description: Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
Study: NCT02750046

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: total hip arthroplasty or proximal femoral nails
Description: Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hip arthroplasty or proximal femoral nails
Description: Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
Study: NCT03489772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03373344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Processing Training
Description: Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
Study: NCT02941328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
Study: NCT04665427

Intervention type: OTHER
Group type: OTHER
Intervention: bilioenteric anastomosis i
Description: The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
Study: NCT01816191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride Cream and Oral Diltiazem
Study: NCT01699126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin is an lipid lowering medication with anti-inflammatory effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin is an lipid lowering medication with anti-inflammatory effect.
Study: NCT02977910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repair of deltoid ligament
Description: intraoperative repair of deltoid ligament combined with ORIF
Study: NCT00786305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime and amikacin
Description: Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftazidime and amikacin
Description: Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
Study: NCT03880045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical TA
Description: A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressin
Description: intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressin
Description: intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: (120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
Study: NCT03012828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Moxidectin is a broad spectrum macrocyclic lactone endectocide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Moxidectin is a broad spectrum macrocyclic lactone endectocide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Moxidectin is a broad spectrum macrocyclic lactone endectocide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Moxidectin is a broad spectrum macrocyclic lactone endectocide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: Moxidectin is a broad spectrum macrocyclic lactone endectocide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00817765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
Study: NCT03373344

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control exercises
Description: Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
Study: NCT02731976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study: NCT00484055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local application of collagen-gentamicin
Description: Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation of the sternotomy with more than six wires
Description: At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
Study: NCT04408170

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care test for SARS-CoV-2
Description: Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care test for SARS-CoV-2
Description: Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care test for SARS-CoV-2
Description: Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2
Study: NCT00969540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Mattress Cover
Description: Active Mattress Cover

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mattress Cover
Description: Placebo Mattress Cover
Study: NCT04271553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
Study: NCT00660075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/d for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 weeks
Study: NCT01082588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study: NCT00817765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole
Description: Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: fosamprenavir tablet 700mg; 1 tablet BID for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: fosamprenavir tablet 700mg; 1 tablet BID for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir 100mg capsule; 1 capsule BID for 10 days
Study: NCT02849834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
Study: NCT03901625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: A manual toothbrush is used to clean teeth surfaces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush
Description: A manual toothbrush is used to clean teeth surfaces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental floss
Description: A dental floss is used to clean inter-proximal areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental floss
Description: A dental floss is used to clean inter-proximal areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterjet
Description: A waterjet is used to clean inter-proximal areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterjet
Description: A waterjet is used to clean inter-proximal areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush
Description: An electric toothbrush is used to clean teeth surfaces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush
Description: An electric toothbrush is used to clean teeth surfaces.
Study: NCT03115411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winged biliary stent (ViaDuct™)
Description: Placement of winged biliary stent at ERCP for management of benign biliary stricture.
Study: NCT02594007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEEQ
Description: Mobile cardiac telemetry system worn externally for a total of 28 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEEQ
Description: Mobile cardiac telemetry system worn externally for a total of 28 days.
Study: NCT02117804

Intervention type: OTHER
Intervention: Early Screen for Discharge Planning
Description: This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
Study: NCT02594007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiocom
Description: Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DocView
Description: Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
Study: NCT00961740

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioural Therapy
Description: See summary

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioural Therapy
Description: See summary

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist condition
Description: See Summary

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist condition
Description: See Summary
Study: NCT02113423

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
Description: 3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
Study: NCT02655757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 5 mg, 1 tablet per day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,1 tablet per day for 12 months
Study: NCT00517010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton beam irradiation and ranibizumab
Description: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
Study: NCT03995095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic interview: kibo protocol
Description: The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
Study: NCT02125838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Supreme
Description: Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube
Description: ETT
Study: NCT05287776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band UVB
Description: Narrow band UVB emitting UVB at wavelength 311nm
Study: NCT02565147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPCI
Description: PPCI for treatment of participants presenting with large STEMI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPCI
Description: PPCI for treatment of participants presenting with large STEMI.
Study: NCT01866059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium silicate cement
Description: Calcium silicate cement
Study: NCT02565147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is an anticoagulant.
Study: NCT00180557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip
Study: NCT01866059

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Cement
Description: Glass Ionomer Cement
Study: NCT00180557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip
Study: NCT03549494

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin-Viusid®
Description: Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
Study: NCT01045434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Magnesium DR 20 mg Capsules
Study: NCT01866059

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin Modified Glass Ionomer Cement
Description: Resin Modified Glass Ionomer Cement
Study: NCT01690741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Nerofe administered intravenously 3x/week
Study: NCT02263781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw
Study: NCT01045434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole Magnesium DR 20 mg Capsules
Study: NCT00959881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil plus placebo
Description: 5- and 10-mg tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5- and 10-mg tablets, single dose
Study: NCT02263781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: Muscle biopsy during planned anesthesia/surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: Muscle biopsy during planned anesthesia/surgery
Study: NCT00959881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Begacestat
Description: 6 x 50-mg capsules, single dose
Study: NCT02106572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abnobaVISCUM 900
Description: intravesical instillation of abnobaVISCUM 900 13 times during treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: intravesical instillation of Mitomycin C 10 times during treatment period
Study: NCT03717636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical evaluation
Description: return of medical evaluation after discharge

Intervention type: OTHER
Group type: OTHER
Intervention: medical evaluation
Description: return of medical evaluation after discharge